Constitutive protein kinase G activation exacerbates stress-induced cardiomyopathy
© 2021 The British Pharmacological Society..
BACKGROUND AND PURPOSE: Heart failure is associated with high morbidity and mortality, and new therapeutic targets are needed. Preclinical data suggest that pharmacological activation of protein kinase G (PKG) can reduce maladaptive ventricular remodelling and cardiac dysfunction in the stressed heart. However, clinical trial results have been mixed and the effects of long-term PKG activation in the heart are unknown.
EXPERIMENTAL APPROACH: We characterized the cardiac phenotype of mice carrying a heterozygous knock-in mutation of PKG1 (Prkg1R177Q/+ ), which causes constitutive, cGMP-independent activation of the kinase. We examined isolated cardiac myocytes and intact mice, the latter after stress induced by surgical transaortic constriction or angiotensin II (Ang II) infusion.
KEY RESULTS: Cardiac myocytes from Prkg1R177Q/+ mice showed altered phosphorylation of sarcomeric proteins and reduced contractility in response to electrical stimulation, compared to cells from wild type mice. Under basal conditions, young PKG1R177Q/+ mice exhibited no obvious cardiac abnormalities, but aging animals developed mild increases in cardiac fibrosis. In response to angiotensin II infusion or fixed pressure overload induced by transaortic constriction, young PKGR177Q/+ mice exhibited excessive hypertrophic remodelling with increased fibrosis and myocyte apoptosis, leading to increased left ventricular dilation and dysfunction compared to wild type litter mates.
CONCLUSION AND IMPLICATIONS: Long-term PKG1 activation in mice may be harmful to the heart, especially in the presence of pressure overload and neurohumoral stress.
LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:179 |
|---|---|
| Enthalten in: |
British journal of pharmacology - 179(2022), 11 vom: 26. Juni, Seite 2413-2429 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schwaerzer, Gerburg K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.05.2022 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bph.15530 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325512833 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325512833 | ||
| 003 | DE-627 | ||
| 005 | 20231225192611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bph.15530 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325512833 | ||
| 035 | |a (NLM)34000062 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schwaerzer, Gerburg K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Constitutive protein kinase G activation exacerbates stress-induced cardiomyopathy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.05.2022 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The British Pharmacological Society. | ||
| 520 | |a BACKGROUND AND PURPOSE: Heart failure is associated with high morbidity and mortality, and new therapeutic targets are needed. Preclinical data suggest that pharmacological activation of protein kinase G (PKG) can reduce maladaptive ventricular remodelling and cardiac dysfunction in the stressed heart. However, clinical trial results have been mixed and the effects of long-term PKG activation in the heart are unknown | ||
| 520 | |a EXPERIMENTAL APPROACH: We characterized the cardiac phenotype of mice carrying a heterozygous knock-in mutation of PKG1 (Prkg1R177Q/+ ), which causes constitutive, cGMP-independent activation of the kinase. We examined isolated cardiac myocytes and intact mice, the latter after stress induced by surgical transaortic constriction or angiotensin II (Ang II) infusion | ||
| 520 | |a KEY RESULTS: Cardiac myocytes from Prkg1R177Q/+ mice showed altered phosphorylation of sarcomeric proteins and reduced contractility in response to electrical stimulation, compared to cells from wild type mice. Under basal conditions, young PKG1R177Q/+ mice exhibited no obvious cardiac abnormalities, but aging animals developed mild increases in cardiac fibrosis. In response to angiotensin II infusion or fixed pressure overload induced by transaortic constriction, young PKGR177Q/+ mice exhibited excessive hypertrophic remodelling with increased fibrosis and myocyte apoptosis, leading to increased left ventricular dilation and dysfunction compared to wild type litter mates | ||
| 520 | |a CONCLUSION AND IMPLICATIONS: Long-term PKG1 activation in mice may be harmful to the heart, especially in the presence of pressure overload and neurohumoral stress | ||
| 520 | |a LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cGMP-dependent protein kinase | |
| 650 | 4 | |a cardiac hypertrophy | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a phosphorylation of sarcomeric proteins | |
| 650 | 4 | |a stress-induced dilated cardiomyopathy | |
| 650 | 7 | |a Angiotensin II |2 NLM | |
| 650 | 7 | |a 11128-99-7 |2 NLM | |
| 650 | 7 | |a Cyclic GMP-Dependent Protein Kinase Type I |2 NLM | |
| 650 | 7 | |a EC 2.7.11.12 |2 NLM | |
| 650 | 7 | |a Cyclic GMP-Dependent Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.12 |2 NLM | |
| 650 | 7 | |a Prkg1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.11.12 |2 NLM | |
| 700 | 1 | |a Casteel, Darren E |e verfasserin |4 aut | |
| 700 | 1 | |a Cividini, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyanaraman, Hema |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Shunhui |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Yusu |e verfasserin |4 aut | |
| 700 | 1 | |a Dalton, Nancy D |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Kirk L |e verfasserin |4 aut | |
| 700 | 1 | |a Dillmann, Wolfgang H |e verfasserin |4 aut | |
| 700 | 1 | |a Boss, Gerry R |e verfasserin |4 aut | |
| 700 | 1 | |a Pilz, Renate B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d 1968 |g 179(2022), 11 vom: 26. Juni, Seite 2413-2429 |w (DE-627)NLM000001325 |x 1476-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:179 |g year:2022 |g number:11 |g day:26 |g month:06 |g pages:2413-2429 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bph.15530 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 179 |j 2022 |e 11 |b 26 |c 06 |h 2413-2429 | ||